Riskpilot← Back to searchSign inGet full accessTeitur Trophics ApS
APSActiveCVR 41058439Palle Juul-Jensens Boulevard 82Research and experimental development on natural sciences and engineering · NACE 7210Est. 202012 employees
Revenue 2024
DKK -6,2M
+54% vs 2023
EBITDA margin
114.9%
-61% vs 2023
Equity ratio
72.9%
Financial strength
Net profit 2024
DKK -6,3M
-131% vs 2023
| Revenue | DKK -6,2M | +54% |
| EBITDA | DKK -7,1M | -61% |
| Net profit | DKK -6,3M | -131% |
| Total assets | DKK 7,5M | -44% |
| Equity | DKK 5,5M | -54% |
| Employees | 12 | — |
Legal name
Teitur Trophics ApS
CVR number
41058439
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
8. januar 2020
Share capital
DKK 234.546
Employees
12 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør og to bestyrelsesmedlemmer i forening, af tre bestyrelsesmedlemmer i forening, eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at forske i, udvikle, producere og sælge bioteknologiske produkter
og medicinalprodukter samt anden virksomhed, der efter ledelsens skøn er forbundet dermed.
Address
Palle Juul-Jensens Boulevard 82
Phone
+4521458605
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | -2.396 | -6.988 | -3.695 | -4.024 | -6.189 |
| Staff expenses | -1.329 | -1.946 | -1.735 | -382 | -923 |
| EBITDA | -3.724 | -8.934 | -5.430 | -4.407 | -7.112 |
| Depreciation & amort. | -0 | -7 | -7 | -9 | -60 |
| EBIT | -3.724 | -8.941 | -5.436 | -4.416 | -7.172 |
| Net financials | -138 | -797 | -1.050 | 939 | 116 |
| Profit before tax | -3.863 | -9.738 | -6.486 | -3.477 | -7.055 |
| Tax | -470 | -1.676 | -952 | -738 | -738 |
| Net profit | -3.392 | -8.062 | -5.534 | -2.739 | -6.317 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 4.576 | 9.075 | 5.109 | 13.317 | 7.478 |
| Equity | -3.352 | -11.415 | -16.949 | 11.771 | 5.453 |
| Long-term debt | 7.401 | 19.747 | 20.756 | 705 | 490 |
| Short-term debt | 527 | 742 | 1.301 | 841 | 1.534 |
| Total debt | 7.928 | 20.489 | 22.057 | 1.546 | 2.024 |
EBITDA margin
-711196100.0%
This company
15.8%
Market median
-4501241239% vs market
20202024
Equity ratio
72.9%
This company
38.2%
Market median
+91% vs market
20202024
Return on equity
-115.8%
This company
18.4%
Market median
-729% vs market
20202024
Net profit margin
-631739700.0%
This company
8.1%
Market median
-7799255656% vs market
20202024
Asset turnover
-0.83×
This company
1.12×
Market median
-174% vs market
20202024
Debt / equity
0.37×
This company
0.62×
Market median
+40% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-08 – 2020-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
SM Management | Management | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2021 | — | — | |
| Chairman | 2021 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 15.0% | 15.0% | 2025 | |
| Individual | 15.0% | 15.0% | 2023 | |
Sunstone Life Science Ventures Fund IV K/S | Company | 15.0% | 15.0% | 2023 |
| Individual | 15.0% | 15.0% | 2023 | |
IMAS Holding ApS | Company | 5.0% | 5.0% | 2023 |
| Individual | 5.0% | 5.0% | 2023 | |
Anders Dalby Holding ApS | Company | 5.0% | 5.0% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
IMAS Holding ApS
Teitur Trophics ApS Board members of Teitur Trophics ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Simon Mølgaard Jensen | Management | 0 companies |
| Susanne Stuffers | Board of Directors | 0 companies |
| Anders Dalby | Board of Directors | 0 companies |
| Charles Henry Large | Chairman | 0 companies |
| Søren Lemonius | Board of Directors | 0 companies |
| Per Fredrik Lehmann | Board of Directors | 0 companies |
| Gregory Davis Jones | Board of Directors | 0 companies |
| Milla Maria Koistinaho | Board of Directors | 0 companies |
| Casper Breum | Board of Directors | 0 companies |
| Mathias Kaas Ollendorff | Board of Directors | 0 companies |